Pediatric AML: From Biology to Clinical Management
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute leukemias. Survival rates have increased over the past few decades to ~70%, due to improved supportive care, optimized risk stratification and intensified chemotherapy. In most children, AML presents as a de novo entity, but in a minority, it is a secondary malignancy. The diagnostic classification of pediatric AML includes a combination of morphology, cytochemistry, immunophenotyping and molecular genetics. Outcome is mainly dependent on the initial response to treatment and molecular and cytogenetic aberrations. Treatment consists of a combination of intensive anthracycline- and cytarabine-containing chemotherapy and stem cell transplantation in selected genetic high-risk cases or slow responders. In general, ~30% of all pediatric AML patients will suffer from relapse, whereas 5%–10% of the patients will die due to disease complications or the side-effects of the treatment. Targeted therapy may enhance anti-leukemic efficacy and minimize treatment-related morbidity and mortality, but requires detailed knowledge of the genetic abnormalities and aberrant pathways involved in leukemogenesis. These efforts towards future personalized therapy in a rare disease, such as pediatric AML, require intensive international collaboration in order to enhance the survival rates of pediatric AML, while aiming to reduce long-term toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circos: An information aesthetic for comparative genomics
Krzywinski, M., Schein, J., Birol, İ., Connors, J., Gascoyne, R., Horsman, D., Jones, S. J., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 10,964 · cited 2×
“The circos plot [73] depicts the frequency of the Type II mutations and co-occurrence of Type I mutations in patients with de novo pediatric cytogenetically”
BackgroundMicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539 · cited 1×
“Differences in microRNA expression levels can classify several types of cancer [104].”
BackgroundBennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602 · cited 1×
“The previously used morphology-based French-American-British (FAB) classification is nowadays replaced by the World Health Organization (WHO) classification, which also takes karyotype and molecular aberrations into account (Table 1) [13,14].”
MethodVardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424 · cited 2×
“The WHO classification of acute myeloid leukemia (AML) and related neoplasms [14].”
BackgroundMethodFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Mutations in epigenetic regulators, such as EZH2, ASXL1 and DNMT3A, add another level of complexity and contribute to both the maturation arrest and proliferative capacity, which are needed to develop AML (Figure 2) [63–71].”
BackgroundRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993 · cited 1×
“In addition to discovering novel gene mutations, next generation sequencing has also proven to be a powerful tool in the study of the clonal evolution of both adult and pediatric AML [98,99].”
BackgroundDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · cited 1×
“These CNVs included aberrations in WT1, NF1 and TET2, the latter being more common in adults than in children [47,65,67,91].”
BackgroundPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370 · cited 1×
“Gene expression profiling could predict the cytogenetic subtypes of AML with high accuracy, although its value for diagnostic purposes remains limited, since most aberrations can be identified with conventional karyotyping [92–95].”
BackgroundSong, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100 · cited 1×
“Recently, germ-line mutations in several genes, such as TP53, RUNX1, GATA2 and CEBPA, have been found in families with an unexplained high risk of AML, suggesting a familial predisposition to develop AML [4–8].”
BackgroundMLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870 · cited 2×
“In addition, the presence of DOT1L, which is recruited into the MLL-complex, is required for the leukemogenic activity of several MLL rearrangements and may be a target for treatment [60,61].”
BackgroundDNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833 · cited 1×
“Epigenetic profiling was able to distinguish cytogenetic subtypes of adult AML [102].”
BackgroundYan, X.-J., Xu, J., Gu, Z.-H., Pan, C.-M., Lu, G., Shen, Y., Shi, J.-Y., Zhu, Y.-M., Tang, L., Zhang, X.-W., et al. (2011) · Nature Genetics · doi:10.1038/ng.788 · Cited by 813 · cited 1×
“Mutations in epigenetic regulators, such as EZH2, ASXL1 and DNMT3A, add another level of complexity and contribute to both the maturation arrest and proliferative capacity, which are needed to develop AML (Figure 2) [63–71].”
BackgroundBENNETT, J. M., CATOVSKY, D., DANIEL, M.-T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-460 · Cited by 737
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 735 · cited 1×
“this [112,113].”
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638 · cited 1×
“The first phase III studies did not show an improvement in disease-free and overall survival in pediatric AML patients, but it was favorable in patients with refractory or relapsed disease and was effective at reducing MRD levels before SCT [75,122–125].”
BackgroundZarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
Garzon, R., Volinia, S., Liu, C.-G., Fernandez-Cymering, C., Palumbo, T., Pichiorri, F., Fabbri, M., Coombes, K., Alder, H., Nakamura, T., et al. (2008) · Blood · doi:10.1182/blood-2007-07-098749 · Cited by 632 · cited 1×
“Profiling studies in adult AML have shown that variations in microRNA expression patterns are associated with subtypes of AML and that specific microRNAs target genes of interest for the biology of AML [105–107].”
BackgroundHahn, C. N., Chong, C.-E., Carmichael, C. L., Wilkins, E. J., Brautigan, P. J., Li, X.-C., Babic, M., Lin, M., Carmagnac, A., Lee, Y. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.913 · Cited by 606 · cited 1×
“Recently, germ-line mutations in several genes, such as TP53, RUNX1, GATA2 and CEBPA, have been found in families with an unexplained high risk of AML, suggesting a familial predisposition to develop AML [4–8].”
BackgroundRubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N. J., Cao, X., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70090-5 · Cited by 584 · cited 1×
“adult patients, studies suggest that there is a benefit for outcome using high-dose cytarabine in induction, but from previous trials, a similar effect in pediatric AML patients could not be confirmed [26,32].”
ResultCreutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Self-citationMolecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 570 · cited 1×
“Only 20%–25% of pediatric AML cases are cytogenetically normal [48,62].”
BackgroundG ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523 · cited 1×
“AML is thought to arise from at least two classes of cooperating genetic events [44].”
BackgroundThe MLL recombinome of acute leukemias in 2013
Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T. S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013) · Leukemia · doi:10.1038/leu.2013.135 · Cited by 491
Self-citationGene expression profiling of pediatric acute myelogenous leukemia
Ross, M. E., Mahfouz, R., Onciu, M., Liu, H.-C., Zhou, X., Song, G., Shurtleff, S. A., Pounds, S., Cheng, C., Ma, J., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1154 · Cited by 448 · cited 1×
“Gene expression profiling could predict the cytogenetic subtypes of AML with high accuracy, although its value for diagnostic purposes remains limited, since most aberrations can be identified with conventional karyotyping [92–95].”
BackgroundBalgobind, B. V., Raimondi, S. C., Harbott, J., Zimmermann, M., Alonzo, T. A., Auvrignon, A., Beverloo, H. B., Chang, M., Creutzig, U., Dworzak, M. N., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215152 · Cited by 445 · cited 1×
“In contrast, poor survival rates were reported in pediatric AML with translocations t(6;11)(q27;q23) and t(10;11)(p12;q23) [80,81].”
BackgroundSelf-citationNew insights to the MLL recombinome of acute leukemias
Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.33 · Cited by 407 · cited 1×
“More than 60 fusion partners have been identified in AML, but the breakpoint of the MLL gene is highly conserved [58,59].”
BackgroundSelf-citationMicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
Jongen-Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. M., & Löwenberg, B. (2008) · Blood · doi:10.1182/blood-2008-01-133355 · Cited by 403 · cited 1×
“Profiling studies in adult AML have shown that variations in microRNA expression patterns are associated with subtypes of AML and that specific microRNAs target genes of interest for the biology of AML [105–107].”
BackgroundLevis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301796 · Cited by 398 · cited 1×
“this [112,113].”
Hollink, I. H. I. M., van den Heuvel-Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Pratcorona, M., Abbas, S., Kuipers, J. E., van Galen, J. F., Beverloo, H. B., Sonneveld, E., Kaspers, G.-J. J. L., et al. (2011) · Blood · doi:10.1182/blood-2011-04-346643 · Cited by 334
Self-citationMutation of CEBPA in Familial Acute Myeloid Leukemia
Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041331 · Cited by 328 · cited 2×
“Recently, germ-line mutations in several genes, such as TP53, RUNX1, GATA2 and CEBPA, have been found in families with an unexplained high risk of AML, suggesting a familial predisposition to develop AML [4–8].”
BackgroundJeha, S., Gaynon, P. S., Razzouk, B. I., Franklin, J., Kadota, R., Shen, V., Luchtman-Jones, L., Rytting, M., Bomgaars, L. R., Rheingold, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8554 · Cited by 308
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304 · cited 1×
“To inhibit signal transduction pathways, such as the Ras-pathway, which is notorious for escaping behavior, which makes the leukemic cell survives despite intensive chemotherapy, combinations of inhibitors may be more promising, and this approach is currently being further explored in synthetic lethality screens, whic…”
BackgroundTreatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
Gibson, B. E. S., Wheatley, K., Hann, I. M., Stevens, R. F., Webb, D., Hills, R. K., De Graaf, S. S. N., Harrison, C. J., & for the United Kingdom Childhood Leukaemia Working Party, A. T. D. C. O. G. (2005) · Leukemia · doi:10.1038/sj.leu.2403924 · Cited by 303 · cited 1×
“The clinical outcome of pediatric AML has improved significantly over the past few decades, with current long-term survival rates of ~70% (Table 2) [20–30].”
BackgroundHarrison, C. J., Hills, R. K., Moorman, A. V., Grimwade, D. J., Hann, I., Webb, D. K. H., Wheatley, K., de Graaf, S. S. N., van den Berg, E., Burnett, A. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8997 · Cited by 302 · cited 1×
“1q22) (together referred to as core binding factor (CBF)-AML), t(15;17)(q22;q21) and 11q23/MLL-rearranged abnormalities (Figure 1A) [49–52].”
BackgroundThe MLL recombinome of acute leukemias
Meyer, C., Schneider, B., Jakob, S., Strehl, S., Attarbaschi, A., Schnittger, S., Schoch, C., Jansen, M. W. J. C., van Dongen, J. J. M., den Boer, M. L., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404150 · Cited by 271 · cited 1×
“More than 60 fusion partners have been identified in AML, but the breakpoint of the MLL gene is highly conserved [58,59].”
BackgroundRaghavan, M., Lillington, D. M., Skoulakis, S., Debernardi, S., Chaplin, T., Foot, N. J., Lister, T. A., & Young, B. D. (2005) · Cancer Research · doi:10.1158/0008-5472.375.65.2 · Cited by 269 · cited 1×
“comparative genomic hybridization (array-CGH) and single-nucleotide polymorphism (SNP) arrays identified several regions with loss of heterozygosity and recurrent copy number variations (CNVs), albeit with low frequency in AML [90].”
BackgroundGröschel, S., Lugthart, S., Schlenk, R. F., Valk, P. J. M., Eiwen, K., Goudswaard, C., van Putten, W. J. L., Kayser, S., Verdonck, L. F., Lübbert, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0646 · Cited by 256 · cited 1×
“Overexpression of EVI1 caused by 3q26 abnormalities predicts an adverse outcome in adult AML, but EVI1 overexpression is not an independent prognostic factor in pediatric AML [86,87].”
Backgroundvon Neuhoff, C., Reinhardt, D., Sander, A., Zimmermann, M., Bradtke, J., Betts, D. R., Zemanová, Z., Starý, J., Bourquin, J., Haas, O. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6321 · Cited by 249 · cited 3×
“In those pediatric patients, the outcome seems to be dependent on other cytogenetic abnormalities in the leukemic cell [52,82].”
BackgroundNatural history of GATA1 mutations in Down syndrome
Ahmed, M. (2004) · Blood · doi:10.1182/blood-2003-10-3383 · Cited by 244 · cited 1×
“genetic aberrations in hematopoietic transcription factors, due to, for instance, the AML-characteristic translocations t(8;21)(q22;q22)/AML1-ETO and 11q23/MLL rearrangements or from mutations in genes, such as NPM1 and CEBPA [7,45–48].”
BackgroundMutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
Goemans, B. F., Zwaan, C. M., Miller, M., Zimmermann, M., Harlow, A., Meshinchi, S., Loonen, A. H., Hählen, K., Reinhardt, D., Creutzig, U., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403870 · Cited by 243 · cited 1×
“Patients with KIT mutations include the imatinib-resistant patients with the D816V/Y mutation, who are sensitive to dasatinib [48,115].”
BackgroundSelf-citationKaspers, G. J. L., Zimmermann, M., Reinhardt, D., Gibson, B. E. S., Tamminga, R. Y. J., Aleinikova, O., Armendariz, H., Dworzak, M. N., Ha, S., Hasle, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7384 · Cited by 241 · cited 1×
“Despite intensive treatment, ~30% of the pediatric patients relapse, and outcome is poor, reflected by the ~30%–40% of patients surviving in the largest and most recent series reported to date [41,42].”
BackgroundCreutzig, U., Zimmermann, M., Bourquin, J., Dworzak, M. N., Fleischhack, G., Graf, N. M., Klingebiel, T. E., Kremens, B., Lehrnbecher, T., von Neuhoff, C., et al. (2013) · Blood · doi:10.1182/blood-2013-02-484097 · Cited by 213
Debernardi, S., Skoulakis, S., Molloy, G., Chaplin, T., Dixon-McIver, A., & Young, B. D. (2007) · Leukemia · doi:10.1038/sj.leu.2404605 · Cited by 207 · cited 1×
“Profiling studies in adult AML have shown that variations in microRNA expression patterns are associated with subtypes of AML and that specific microRNAs target genes of interest for the biology of AML [105–107].”
BackgroundClinical importance of cytogenetics in acute myeloid leukaemia
Mrózek, K., Heinonen, K., & Bloomfield, C. D. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2000.0114 · Cited by 204 · cited 1×
“The majority of chromosomal abnormalities is detected by conventional karyotyping and complemented with FISH or reverse transcriptase PCR to detect relevant (cryptic) translocations, fusion genes or loss of chromosome material [16].”
BackgroundPession, A., Masetti, R., Rizzari, C., Putti, M. C., Casale, F., Fagioli, F., Luciani, M., Lo Nigro, L., Menna, G., Micalizzi, C., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491621 · Cited by 202 · cited 3×
“The described poor prognostic abnormalities in adult AML of chromosomes 3q and 5q and the monosomal karyotypes are rare in children [30,83–85].”
BackgroundWouters, B. J., Jordà, M. A., Keeshan, K., Louwers, I., Erpelinck-Verschueren, C. A. J., Tielemans, D., Langerak, A. W., He, Y., Yashiro-Ohtani, Y., Zhang, P., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073486 · Cited by 199 · cited 1×
“Gene expression profiling could predict the cytogenetic subtypes of AML with high accuracy, although its value for diagnostic purposes remains limited, since most aberrations can be identified with conventional karyotyping [92–95].”
BackgroundCooper, T. M., Franklin, J., Gerbing, R. B., Alonzo, T. A., Hurwitz, C., Raimondi, S. C., Hirsch, B., Smith, F. O., Mathew, P., Arceci, R. J., et al. (2012) · Cancer · doi:10.1002/cncr.26190 · Cited by 199 · cited 2×
“The first phase III studies did not show an improvement in disease-free and overall survival in pediatric AML patients, but it was favorable in patients with refractory or relapsed disease and was effective at reducing MRD levels before SCT [75,122–125].”
BackgroundFamilial myelodysplasia and acute myeloid leukaemia – a review
Owen, C., Barnett, M., & Fitzgibbon, J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06909.x · Cited by 187 · cited 1×
“Recently, germ-line mutations in several genes, such as TP53, RUNX1, GATA2 and CEBPA, have been found in families with an unexplained high risk of AML, suggesting a familial predisposition to develop AML [4–8].”
BackgroundMechanisms of leukemogenesis by MLL fusion proteins
Marschalek, R. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08459.x · Cited by 184 · cited 1×
“In addition, the presence of DOT1L, which is recruited into the MLL-complex, is required for the leukemogenic activity of several MLL rearrangements and may be a target for treatment [60,61].”
BackgroundThe clinical significance of cytogenetic abnormalities in acute myeloid leukaemia
Grimwade, D. J. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2001.0152 · Cited by 179 · cited 1×
“1q22) (together referred to as core binding factor (CBF)-AML), t(15;17)(q22;q21) and 11q23/MLL-rearranged abnormalities (Figure 1A) [49–52].”
Backgroundfor the European Society for Blood and Marrow Transplantation EBMT, Passweg, J. R., Baldomero, H., Peters, C., Gaspar, H. B., Cesaro, S., Dreger, P., Duarte, R. F., Falkenburg, J. H. F., Farge-Bancel, D., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.55 · Cited by 178 · cited 1×
“Currently, several trials include minimal residual disease (MRD) levels after Courses 1 or 2 in risk stratification for SCT [37–40].”
BackgroundLeukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
Deshpande, A. J., Chen, L., Fazio, M., Sinha, A. U., Bernt, K. M., Banka, D., Dias, S., Chang, J., Olhava, E. J., Daigle, S. R., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465120 · Cited by 174 · cited 1×
“Interestingly, these DOT1L inhibitors also seem valuable in the treatment of t(6;11)(q27;q23)-positive cells, which lack DOT1L in the formed complex, indicating that this drug is able to target aberrant H3K79 methylation [121].”
BackgroundHasle, H., Alonzo, T. A., Auvrignon, A., Béhar, C., Chang, M. N., Creutzig, U., Fischer, A., Forestier, E., Fynn, A., Haas, O. A., et al. (2007) · Blood · doi:10.1182/blood-2006-10-051342 · Cited by 173 · cited 2×
“In those pediatric patients, the outcome seems to be dependent on other cytogenetic abnormalities in the leukemic cell [52,82].”
BackgroundHollink, I. H. I. M., Zwaan, C. M., Zimmermann, M., Arentsen-Peters, T. C. J. M., Pieters, R., Cloos, J., Kaspers, G. J. L., de Graaf, S. S. N., Harbott, J., Creutzig, U., et al. (2009) · Leukemia · doi:10.1038/leu.2008.313 · Cited by 166
Self-citationde Rooij, J. D. E., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., van Galen, J. F., Beverloo, H. B., Baruchel, A., Trka, J., Reinhardt, D., Sonneveld, E., Zimmermann, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.87 · Cited by 163 · cited 2×
“Of interest in these cases, specific Type II mutations and translocations are identified in ~70% of the cases, such as NPM1 mutations, biallelic CEBPA mutations, as well as the cryptic translocations, NUP98/NSD1, all invisible with conventional karyotyping and, hence, requiring additional molecular diagnostics (Figure…”
BackgroundResultSelf-citationLink, D. C. (2011) · JAMA · doi:10.1001/jama.2011.473 · Cited by 158 · cited 1×
“Recently, germ-line mutations in several genes, such as TP53, RUNX1, GATA2 and CEBPA, have been found in families with an unexplained high risk of AML, suggesting a familial predisposition to develop AML [4–8].”
BackgroundStumpel, D. J. P. M., Schneider, P., van Roon, E. H. J., Boer, J. M., de Lorenzo, P., Valsecchi, M. G., de Menezes, R. X., Pieters, R., & Stam, R. W. (2009) · Blood · doi:10.1182/blood-2009-06-227660 · Cited by 157
van der Velden, V. H. J., van der Sluijs‐Gelling, A. J., Gibson, B. E. S., Marvelde, J. G. T., Hoogeveen, P. G., Hop, W. C. J., Wheatley, K., Bierings, M., Schuurhuis, G. J., de Graaf, S. S. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.153 · Cited by 143 · cited 1×
“(CR) rate after one or two courses or applying minimal-residual disease measurements, which in AML is mainly based on flow-cytometry [31].”
BackgroundSlats, A. M., Egeler, R. M., den Berg, A. V. D. D.-V., Korbijn, C., Hählen, K., Kamps, W. A., Veerman, A. J. P., & Zwaan, C. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403665 · Cited by 141 · cited 1×
“Nevertheless, the high frequency of treatment-related deaths (5%–10%), both in treatment protocols for newly-diagnosed, as well as for relapsed disease, and the occurrence of long-term side effects, such as anthracycline-induced cardiomyopathy, illustrate that further intensification of chemotherapy seems no longer fe…”
BackgroundSelf-citationBalgobind, B. V., Van Vlierberghe, P., van den Ouweland, A. M. W., Beverloo, H. B., Terlouw-Kromosoeto, J. N. R., van Wering, E. R., Reinhardt, D., Horstmann, M., Kaspers, G. J. L., Pieters, R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095075 · Cited by 139 · cited 1×
“These CNVs included aberrations in WT1, NF1 and TET2, the latter being more common in adults than in children [47,65,67,91].”
BackgroundSelf-citationTönnies, H., Huber, S. T., Kühl, J., Gerlach, A., Ebell, W., & Neitzel, H. (2003) · Blood · doi:10.1182/blood-2002-10-3243 · Cited by 132 · cited 1×
“Germline affected individuals, such as those with Fanconi anemia or Bloom syndrome, have an increased risk for developing AML as a secondary malignancy [2,3].”
BackgroundBalgobind, B. V., van den Heuvel‐Eibrink, M. M., Menezes, R. X. D., Reinhardt, D., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., van Wering, E. R., Kaspers, G. J. L., Cloos, J. J., de Bont, E. S. J. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.029660 · Cited by 124 · cited 1×
“Gene expression profiling could predict the cytogenetic subtypes of AML with high accuracy, although its value for diagnostic purposes remains limited, since most aberrations can be identified with conventional karyotyping [92–95].”
BackgroundSelf-citationBalgobind, B. V., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., Zimmermann, M., Harbott, J., Beverloo, H. B., von Bergh, A. R. M., Cloos, J. J., Kaspers, G. J. L., de Haas, V., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.038976 · Cited by 123 · cited 4×
“Patients with KIT mutations include the imatinib-resistant patients with the D816V/Y mutation, who are sensitive to dasatinib [48,115].”
BackgroundInfluentialSelf-citationHijiya, N., Thomson, B. G., Isakoff, M. S., Silverman, L. B., Steinherz, P. G., Borowitz, M. J., KADOTA, R. P., Cooper, T. M., Shen, V., Dahl, G. V. H., et al. (2011) · Blood · doi:10.1182/blood-2011-08-374710 · Cited by 120 · cited 1×
“cyclophosphamide and etoposide [128].”
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 110 · cited 1×
“To inhibit signal transduction pathways, such as the Ras-pathway, which is notorious for escaping behavior, which makes the leukemic cell survives despite intensive chemotherapy, combinations of inhibitors may be more promising, and this approach is currently being further explored in synthetic lethality screens, whic…”
BackgroundHo, P. A., Alonzo, T. A., Kopecky, K. J., Miller, K. L., Kuhn, J., Zeng, R., Gerbing, R. B., Raimondi, S., Hirsch, B. A., Oehler, V. G., et al. (2010) · Leukemia · doi:10.1038/leu.2010.56 · Cited by 102 · cited 1×
“Mutations in epigenetic regulators, such as EZH2, ASXL1 and DNMT3A, add another level of complexity and contribute to both the maturation arrest and proliferative capacity, which are needed to develop AML (Figure 2) [63–71].”
BackgroundPediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
Seif, A. E. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.04.005 · Cited by 99 · cited 1×
“Germline affected individuals, such as those with Fanconi anemia or Bloom syndrome, have an increased risk for developing AML as a secondary malignancy [2,3].”
Backgroundvon Bergh, A. R. M., van Drunen, E., van Wering, E. R., van Zutven, L. J. C. M., Hainmann, I., Lönnerholm, G., Meijerink, J. P. P., Pieters, R., & Beverloo, H. B. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20335 · Cited by 98 · cited 2×
“Some translocations, for example t(1;22)(p13;q13), t(7;12)(q36;p13) and t(11;12)(p15;p13), are specific for children and are rarely or never found in adults [17–19,53–57].”
BackgroundEVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia
Balgobind, B. V., Lugthart, S., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., van Wering, E. R., de Graaf, S. S. N., Reinhardt, D., Creutzig, U., Kaspers, G. J. L., de Bont, E. S. J. M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.47 · Cited by 97 · cited 1×
“Overexpression of EVI1 caused by 3q26 abnormalities predicts an adverse outcome in adult AML, but EVI1 overexpression is not an independent prognostic factor in pediatric AML [86,87].”
BackgroundSelf-citationHoribe, K., Saito, A. M., Takimoto, T., Tsuchida, M., Manabe, A., Shima, M., Ohara, A., & Mizutani, S. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1364-2 · Cited by 97 · cited 1×
“The clinical outcome of pediatric AML has improved significantly over the past few decades, with current long-term survival rates of ~70% (Table 2) [20–30].”
BackgroundZwaan, C. M., Rizzari, C., Mechinaud, F. M., Lancaster, D. L., Lehrnbecher, T., van der Velden, V. H. J., Beverloo, B., den Boer, M. L., Pieters, R., Reinhardt, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8280 · Cited by 95 · cited 1×
“A phase I study of dasatinib has been completed in children [116].”
BackgroundSelf-citationZwaan, C. M., Reinhardt, D., Zimmerman, M., Hasle, H., Starý, J., Stark, B., Dworzak, M. N., Creutzig, U., Kaspers, G. J. L., & on behalf of the International BFM Study Group on Paediatric AML (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08011.x · Cited by 91
Self-citationLee, Y., Kim, I., Yoon, S., Park, S., Cheong, J., Min, Y. H., Lee, J., Bang, S., Yi, H. G., Kim, C. S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12256 · Cited by 90 · cited 1×
“Azacitidine, another hypomethylating agent, and decitabine show comparable treatment efficacy, but azacitidine may result in less adverse events [132].”
BackgroundRubnitz, J. E., Raimondi, S., Halbert, A., Tong, X., Srivastava, D. K., Razzouk, B. I., Pui, C., Downing, J. R., Ribeiro, R., & Behm, F. (2002) · Leukemia · doi:10.1038/sj.leu.2402633 · Cited by 88 · cited 1×
“CBF-AML is a favorable prognostic subgroup [48,52,79].”
Hollink, I. H. I. M., van den Heuvel‐Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Zimmermann, M., Peeters, J. K., Valk, P. J. M., Balgobind, B. V., Sonneveld, E., Kaspers, G. J. L., de Bont, E. S. J. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031336 · Cited by 86
Self-citationWeiss, B., Vora, A., Huberty, J. P., Hawkins, R. A., & Matthay, K. K. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200307000-00009 · Cited by 85 · cited 1×
“These are typically characterized by either MLL-rearrangements or by monosomy 7 [10,11].”
BackgroundBecton, D. L. (2005) · Blood · doi:10.1182/blood-2004-08-3218 · Cited by 80
Anthias, C., Dignan, F. L., Morilla, R. M., Morilla, A. M., Ethell, M. E., Potter, M. N., & Shaw, B. E. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.9 · Cited by 80 · cited 1×
“Currently, several trials include minimal residual disease (MRD) levels after Courses 1 or 2 in risk stratification for SCT [37–40].”
BackgroundPession, A., Rondelli, R., Basso, G., Rizzari, C., Testi, A. M., Fagioli, F., Stefano, P. D., & Locatelli, F. (2005) · Leukemia · doi:10.1038/sj.leu.2403869 · Cited by 79
Entz‐Werlé, N., Suciu, S., ten Bosch, J. V. D. W., VILMER, E., Bertrand, Y., Benoît, Y., Margueritte, G., Plouvier, E., Boutard, P., Vandecruys, E., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403932 · Cited by 75
TET2 mutations in childhood leukemia
Langemeijer, S. M. C., Jansen, J. H., Hooijer, J. D., van Hoogen, P., Stevens-Linders, E., Massop, M., Waanders, E., van Reijmersdal, S. V., Stevens‐Kroef, M., Zwaan, C. M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.243 · Cited by 72 · cited 1×
“These CNVs included aberrations in WT1, NF1 and TET2, the latter being more common in adults than in children [47,65,67,91].”
BackgroundSelf-citationRecurrence of OTT–MAL fusion in t(1;22) of infant AML‐M7
Mercher, T., Coniat, M. L., Nguyen‐Khac, F., Ballerini, P. F., Mauchauffé, M., Bui, H., Pellegrino, B., Radford‐Weiss, I., Valensi, F., Mugneret, F., et al. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1208 · Cited by 61 · cited 2×
“Some translocations, for example t(1;22)(p13;q13), t(7;12)(q36;p13) and t(11;12)(p15;p13), are specific for children and are rarely or never found in adults [17–19,53–57].”
BackgroundBurnett, A. K., Russell, N. H., Culligan, D. J., Cavanagh, J. D., Kell, J., Wheatley, K., Virchis, A., Hills, R. K., & Milligan, D. W. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09165.x · Cited by 56 · cited 1×
“, MEK-inhibitors, after studies using farnesyl transferase inhibitors failed to show a benefit in older patients with AML [118].”
BackgroundOorschot, A. A. D.-V., Katsman-Kuipers, J. E., Arentsen-Peters, S. T. C. J. M., Schotte, D., de Haas, V., Trka, J., Baruchel, A., Reinhardt, D., Pieters, R., Zwaan, C. M., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23279 · Cited by 55
Self-citationHollink, I. H. I. M., Feng, Q., Oorschot, A. A. D.-V., Arentsen-Peters, S. T. C. J. M., Verboon, L., Zhang, P., de Haas, V., Reinhardt, D., Creutzig, U., Trka, J., et al. (2011) · Leukemia · doi:10.1038/leu.2011.210 · Cited by 39
Self-citationCytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML
Simmons, H., Oseth, L., Nguyen, P. L., O’Leary, M., Conklin, K., & Hirsch, B. A. (2002) · Leukemia · doi:10.1038/sj.leu.2402773 · Cited by 34 · cited 1×
“Some translocations, for example t(1;22)(p13;q13), t(7;12)(q36;p13) and t(11;12)(p15;p13), are specific for children and are rarely or never found in adults [17–19,53–57].”
BackgroundLeonard, S. M., Perry, T., Woodman, C. B. J., & Kearns, P. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087475 · Cited by 33 · cited 1×
“In xenograft models, treatment of AML with a combination of decitabine, a hypomethylating agent, and cytarabine was more effective at reducing tumor burden in comparison to cytarabine alone [130].”
High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)
Katsman-Kuipers, J. E., Coenen, E. A., Balgobind, B. V., Starý, J., Baruchel, A., de Haas, V., de Bont, E. S. J. M., Reinhardt, D., Kaspers, G. J. L., Cloos, J. J., et al. (2010) · Blood · doi:10.1182/blood-2010-05-286138 · Cited by 32 · cited 1×
“Nevertheless, novel genes involved in the pathogenesis of pediatric AML subtypes were identified using this method, such as BRE and IGSF4 [96,97].”
MethodSelf-citationHigh BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome
Balgobind, B. V., Zwaan, C. M., Reinhardt, D., Arentsen-Peters, T. C. J. M., Hollink, I. H. I. M., de Haas, V., Kaspers, G. J. L., de Bont, E. S. J. M., Baruchel, A., Starý, J., et al. (2010) · Leukemia · doi:10.1038/leu.2010.211 · Cited by 29 · cited 1×
“Nevertheless, novel genes involved in the pathogenesis of pediatric AML subtypes were identified using this method, such as BRE and IGSF4 [96,97].”
MethodSelf-citationKohlmann, A., Martinelli, G., Alikian, M., Artusi, V., Auber, B., Beličková, M., Bronzini, I., Cazzaniga, G., Chiaretti, S., Ernst, T., et al. (2013) · Blood · doi:10.1182/blood.v122.21.743.743 · Cited by 15
Valerio, D. G., Katsman-Kuipers, J. E., Jansen, J. H., Verboon, L., de Haas, V., Starý, J., Baruchel, A., Zimmermann, M., Pieters, R., Reinhardt, D., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.094565 · Cited by 14 · cited 1×
“Mutations in epigenetic regulators, such as EZH2, ASXL1 and DNMT3A, add another level of complexity and contribute to both the maturation arrest and proliferative capacity, which are needed to develop AML (Figure 2) [63–71].”
BackgroundSelf-citationKohlmann, A., Martinelli, G., Hofmann, W., Kronnie, G. T., Chiaretti, S., Preudhomme, C., Tagliafico, E., Hernández‐Rivas, J. M., Gabriel, C., Lion, T., et al. (2012) · Blood · doi:10.1182/blood.v120.21.1399.1399 · Cited by 11
Metadata
- Authors
- De Rooij, J., Zwaan, C., & Van den Heuvel-Eibrink, M.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2015-01-09
- Volume
- 4
- Issue
- 1
- Pages
- 127-149
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2002187983
- Cited by
- 208
- References
- 94
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.